These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 8098175

  • 1. Early markers of HIV infection and subclinical disease progression.
    Dolan MJ, Lucey DR, Hendrix CW, Melcher GP, Spencer GA, Boswell RN.
    Vaccine; 1993; 11(5):548-51. PubMed ID: 8098175
    [Abstract] [Full Text] [Related]

  • 2. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L, Martin NL, Kostuchenko P, Beckett L, Rautonen J, Cheng SC, Wara DW.
    AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
    [Abstract] [Full Text] [Related]

  • 3. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.
    Lafeuillade A, Tamalet C, Pellegrino P, de Micco P, Vignoli C, Quilichini R.
    J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1028-33. PubMed ID: 7916049
    [Abstract] [Full Text] [Related]

  • 4. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR, Lizioli A, Arcidiacono I, Cantaluppi P, Filippi C, Sobatti D, Bedarida G, D'Agostino F, Cambie G, Nardella ML.
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
    Müller F, Frøland SS, Aukrust P, Fagerhol MK.
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
    [Abstract] [Full Text] [Related]

  • 7. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users.
    Chaisson RE, Taylor E, Margolick JB, Muñoz A, Solomon L, Cohn S, Nelson KE, Vlahov D.
    J Acquir Immune Defic Syndr (1988); 1992 Sep; 5(5):456-60. PubMed ID: 1348535
    [Abstract] [Full Text] [Related]

  • 8. Immune activation markers and AIDS prognosis.
    Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR.
    AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
    [Abstract] [Full Text] [Related]

  • 9. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J.
    BMJ; 1991 Jan 12; 302(6768):73-8. PubMed ID: 1671651
    [Abstract] [Full Text] [Related]

  • 10. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection.
    Fuchs D, Krämer A, Reibnegger G, Werner ER, Dierich MP, Goedert JJ, Wachter H.
    Infection; 1991 Jan 12; 19 Suppl 2():S98-102. PubMed ID: 1673120
    [Abstract] [Full Text] [Related]

  • 11. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
    Bass HZ, Hardy WD, Mitsuyasu RT, Taylor JM, Wang YX, Fischl MA, Spector SA, Richman DD, Fahey JL.
    J Acquir Immune Defic Syndr (1988); 1992 Jan 12; 5(3):215-21. PubMed ID: 1346807
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of serum beta 2-microglobulin in HIV infection.
    Krämer A, Goedert JJ, Wachter H, Fuchs D.
    Lancet; 1992 Aug 08; 340(8815):371. PubMed ID: 1379663
    [No Abstract] [Full Text] [Related]

  • 13. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL, Spear GT, Lindstrom MJ, Kessler HA, Borden EC, Phair J, Landay AL.
    AIDS; 1991 Mar 08; 5(3):289-93. PubMed ID: 2059368
    [Abstract] [Full Text] [Related]

  • 14. Surrogate markers for AIDS treatment.
    Jacobson M.
    Nurs Times; 1991 Mar 08; 87(22):49. PubMed ID: 1675013
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of spinal fluid beta 2-microglobulin levels with CD4+ T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1.
    Lucey DR, McGuire SA, Clerici M, Hall K, Benton J, Butzin CA, Ward WW, Shearer G, Boswell RN, Hendrix CW.
    J Infect Dis; 1991 May 08; 163(5):971-5. PubMed ID: 1673466
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression.
    Shi M, Taylor JM, Fahey JL, Hoover DR, Muñoz A, Kingsley LA.
    J Clin Immunol; 1997 Jan 08; 17(1):43-52. PubMed ID: 9049785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.